Drugs / OPC-61815
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05439148 | Jun → Sep 2022 | — | Otsuka Beijing Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT04182958 | Nov → Dec 2019 | — | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03510663 | May → Jul 2018 | congestive heart failure | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03962101 | Jun 2019 → Jun 2020 | congestive heart failure | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03772041 | Jan 2019 → Jul 2020 | congestive heart failure | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03254108 | Nov 2017 → Apr 2018 | congestive heart failure | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-03-22 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Has Filed an Application in Japan for Regulatory Approval of OPC-61815, a V -Receptor Antagonist for the Treatment of Cardiac Edema2 otsuka.co.jp ↗ |
| 2020-10-12 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Positive Top-Line Results in Phase 3 Trial of OPC-61815, a V -Receptor Antagonist for the Treatment of Cardiac Edema2 otsuka.co.jp ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPC-61815 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03772041 ↗ |
| Route | Intravenous | “intravenous administration” NCT03254108 ↗ |